NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Ulysses Neuroscience

Ulysses Neuroscience

Private
DublinHealthcare & Life Scienceshttps://ulysses-neuro.com/

Last Round

Early Funding

Apr 17, 2024

Total Funding Raised

$530,000

Company Overview

Ulysses Neuroscience is a contract research organization that provides preclinical and clinical research services to pharmaceutical and biotech companies to accelerate drug discovery for neuropsychiatric, neurodegenerative, and rare neurological disorders.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Clinical Trials, Biotechnology, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

contract research organizationCROCNS drug developmenttranslational medicinebiomarker researchpreclinical researchneuroscience researchiPSC neuronal modelsIND-enabling studiesneurodegenerative disordersdrug discoverylab servicesoutsourced R&Dneuropsychiatric researchpsychedelic research

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Ulysses Neuroscience Comparables

Compare Ulysses Neuroscience with similar companies based on industry and business-model similarity.

Ulysses Neuroscience comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Vivocore Inc.
84%
MD Biosciences
82%
Neuroservices-Alliance
80%

Ulysses Neuroscience Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingApr 17, 2024

Key People

Founding team and executive leadership

Massimiliano Bianchi

Founder President & CEO

Founding Team

Ulysses Neuroscience Investors

Notable investors and investment history

Ulysses Neuroscience investors
InvestorRounds
Growing CapitalEarly Funding
Enterprise IrelandEarly Funding

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 3, 2026

    Grew 36% QoQ from 11 to 15 employees.

  • Apr 19, 2025

    Grew 57% QoQ from 7 to 11 employees.

Ulysses Neuroscience Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Ulysses Neuroscience Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Ulysses Neuroscience's valuation, stock price, and market status.

Firmographic Details

HeadquartersDublin
Employee Range19
Year Founded2019
Last FundingApr 17, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.